BC Extra | Jan 30, 2015
Company News

Alexion founder Bell to retire as CEO

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said principal founder Leonard Bell will retire as CEO, effective April 1, while remaining chairman. COO David Hallal, who joined Alexion in 2006, will succeed Bell as CEO. Hallal took a...
BC Week In Review | Sep 22, 2014
Company News

Ophthotech, Novartis deal

Ophthotech received a $50 million payment from Novartis under a May deal granting the pharma exclusive, ex-U.S. rights to develop and commercialize Fovista . The milestone was triggered by the enrollment of an undisclosed number of...
BC Week In Review | Aug 18, 2014
Clinical News

Fovista: Phase IIa started

Ophthotech began an open-label, U.S. Phase IIa trial to evaluate Fovista in combination with anti-VEGF therapy in about 100 patients with wet AMD. Fovista is in Phase III testing to treat wet AMD, with top-line...
BC Week In Review | May 26, 2014
Company News

Ophthotech, Novartis deal

Ophthotech granted Novartis exclusive, ex-U.S. rights to develop and commercialize Fovista , which is in Phase III testing to treat wet age-related macular degeneration (AMD). Ophthotech, which retains sole commercialization rights in the U.S., will receive...
BC Week In Review | Feb 3, 2014
Company News

Ophthotech, Novo deal

Ophthotech received a second $41.7 million tranche from Novo under a 2013 deal granting Novo low- to mid-single digit royalties on sales of Fovista. The payment was triggered by Ophthotech reaching an initial enrollment milestone...
BC Extra | Sep 26, 2013
Financial News

Ophthotech raises $167.2 million in IPO

Ophthotech Corp. (NASDAQ:OPHT) jumped $4.30 (20%) to $26.30 on Wednesday in its first day of trading after raising $167.2 million in an IPO priced above its proposed range. Ophthotech sold 7.6 million shares at $22,...
BC Extra | Sep 25, 2013
Financial News

Ophthotech amends IPO

Ophthotech Corp. (New York, N.Y.) again amended its IPO and now plans to sell 7.6 million shares at $19-$20. At the $19.50 midpoint, the company would raise $148.2 million and be valued at $587.2 million....
BC Extra | Sep 10, 2013
Financial News

Ophthotech sets IPO range

Ophthotech Corp. (New York, N.Y.) amended its IPO and now plans to sell 5.7 million shares at $16-$19. At the $17.50 midpoint, the company would raise $100.1 million and be valued at $494 million. Morgan...
BC Week In Review | Sep 2, 2013
Clinical News

Fovista: Phase III started

Ophthotech began the first of 3 sham-controlled, international Phase III trials evaluating intravitreal injections of 1.5 mg Fovista in about 1,866 newly diagnosed wet AMD patients. According to in an S-1 filed by Ophthotech, the...
BC Extra | Aug 15, 2013
Financial News

Ophthotech files for IPO

Ophthotech Corp. (New York, N.Y.) filed to raise up to $85 million in an IPO underwritten by Morgan Stanley; JPMorgan; Leerink; and Stifel. By year end, Ophthotech plans to start a Phase III trial to...
Items per page:
1 - 10 of 40
BC Extra | Jan 30, 2015
Company News

Alexion founder Bell to retire as CEO

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said principal founder Leonard Bell will retire as CEO, effective April 1, while remaining chairman. COO David Hallal, who joined Alexion in 2006, will succeed Bell as CEO. Hallal took a...
BC Week In Review | Sep 22, 2014
Company News

Ophthotech, Novartis deal

Ophthotech received a $50 million payment from Novartis under a May deal granting the pharma exclusive, ex-U.S. rights to develop and commercialize Fovista . The milestone was triggered by the enrollment of an undisclosed number of...
BC Week In Review | Aug 18, 2014
Clinical News

Fovista: Phase IIa started

Ophthotech began an open-label, U.S. Phase IIa trial to evaluate Fovista in combination with anti-VEGF therapy in about 100 patients with wet AMD. Fovista is in Phase III testing to treat wet AMD, with top-line...
BC Week In Review | May 26, 2014
Company News

Ophthotech, Novartis deal

Ophthotech granted Novartis exclusive, ex-U.S. rights to develop and commercialize Fovista , which is in Phase III testing to treat wet age-related macular degeneration (AMD). Ophthotech, which retains sole commercialization rights in the U.S., will receive...
BC Week In Review | Feb 3, 2014
Company News

Ophthotech, Novo deal

Ophthotech received a second $41.7 million tranche from Novo under a 2013 deal granting Novo low- to mid-single digit royalties on sales of Fovista. The payment was triggered by Ophthotech reaching an initial enrollment milestone...
BC Extra | Sep 26, 2013
Financial News

Ophthotech raises $167.2 million in IPO

Ophthotech Corp. (NASDAQ:OPHT) jumped $4.30 (20%) to $26.30 on Wednesday in its first day of trading after raising $167.2 million in an IPO priced above its proposed range. Ophthotech sold 7.6 million shares at $22,...
BC Extra | Sep 25, 2013
Financial News

Ophthotech amends IPO

Ophthotech Corp. (New York, N.Y.) again amended its IPO and now plans to sell 7.6 million shares at $19-$20. At the $19.50 midpoint, the company would raise $148.2 million and be valued at $587.2 million....
BC Extra | Sep 10, 2013
Financial News

Ophthotech sets IPO range

Ophthotech Corp. (New York, N.Y.) amended its IPO and now plans to sell 5.7 million shares at $16-$19. At the $17.50 midpoint, the company would raise $100.1 million and be valued at $494 million. Morgan...
BC Week In Review | Sep 2, 2013
Clinical News

Fovista: Phase III started

Ophthotech began the first of 3 sham-controlled, international Phase III trials evaluating intravitreal injections of 1.5 mg Fovista in about 1,866 newly diagnosed wet AMD patients. According to in an S-1 filed by Ophthotech, the...
BC Extra | Aug 15, 2013
Financial News

Ophthotech files for IPO

Ophthotech Corp. (New York, N.Y.) filed to raise up to $85 million in an IPO underwritten by Morgan Stanley; JPMorgan; Leerink; and Stifel. By year end, Ophthotech plans to start a Phase III trial to...
Items per page:
1 - 10 of 40